

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,846,427 B2
APPLICATION NO. : 10/582027
DATED : December 7, 2010
INVENTOR(S) : Maria Dorly Del Curto

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1.

Line 60, "Burkit's lymphoma" should read --Burkitt's lymphoma--.

Column 2.

Line 10, "There is a duster" should read --There is a cluster--.

Line 19, "agents can are sometimes" should read --agents are sometimes--.

Lines 29-30, "166 amino acid" should read --166 amino acids--.

Column 3.

Line 4, "cydodextrins are" should read --cyclodextrins are--.

Line 18, "(2,6-dimethyl)-beta-cyclodextrin" should read
--(2,6-di-O-methyl)-beta-cyclodextrin--.

Line 31, "has bee" should read --has been--.

Line 32, "T. Ide" should read --T. Irie--.

Line 40, "stabilization if" should read --stabilization of--.

Column 4.

Line 2, "hum an serum" should read --human serum--.

Line 58, "polynucleotide's" should read --polynucleotides--.

Column 5.

Line 7, "amino adds" should read --amino acids--.


Line 14, "amino add" should read --amino acid--.

Column 7.

Line 65, "sulfuric add, and salts with organic adds" should read
--sulfuric acid, and salts with organic acids--.

Line 66, "oxalic add" should read --oxalic acid--.

Signed and Sealed this
First Day of March, 2011



David J. Kappos
Director of the United States Patent and Trademark Office

Column 8.

Line 7, “so called” should read --so-called--.

Line 23, “amino add” should read --amino acid--.

Line 32, “tripe tide” should read --tripeptide--.

Line 43, “an IgG₂ molecule.” should read --an Ig molecule.--.

Lines 64-65, “80 000 IU/kg and 200 000” should read --80,000 IU/kg and 200,000--.

Column 9.

Line 9, “one, twice” should read --once, twice--.

Line 15, “IFN-β In the” should read --IFN-β in the--.

Column 10.

Lines 42-43, “hydroxypropyl-gaamma-cyclodextrin” should read
--hydroxypropyl-gamma-cyclodextrin--.

Line 45, “or GIBCD)” should read --or G₁BCD)--.

Line 50, “maltotriosylgamma-cyclodextrin” should read
--maltotriosyl-gamma-cyclodextrin--.

Lines 52-53, “maltosyl-beta-cydodextrin/dimaltosyl-beta-dodextrin” should read
--maltosyl-beta-cyclodextrin/dimaltosyl-beta-cyclodextrin--.

Column 11.

Line 21, “bacterostatic” should read --bacteriostatic--.

Line 26, “product Examples” should read --product. Examples--.

Column 13.

Line 4, “IFN beta” should read --IFN-beta--.

Line 14, “in the are buffer” should read --in the art. Buffer--.

Column 15.

Line 40, “the invention include” should read --the invention includes--.

Column 16.

Line 53, “amount if” should read --amount of--.

Line 65, “amount if” should read --amount of--.

Column 17.

Line 7, “malting” should read --melting--.

Line 46, “and 5(0x M)” should read --and 500x M--.

Column 18.

Line 48, “5 p” should read --5 μ--.

Line 59, “up to 10 μg” should read -- up to 100μg--.

CERTIFICATE OF CORRECTION (continued)

Page 3 of 3

U.S. Pat. No. 7,846,427 B2

Column 19.

Line 5, "Hydroxypropyl-betacyclodextrin" should read

--Hydroxypropyl-beta-cyclodextrin--.

Line 56, "isotonidity" should read --isotonicity--.

Column 20.

Line 26, "manner at" should read --manner: at--.

Line 31, "excipient interferon" should read --excipient/interferon--.

Column 23.

Line 12, "about 4-0)" should read --about 4.0)--.

Line 14, "diluted 12" should read --diluted 1:2--.

Line 21, "(OD)_{380 min}" should read --(OD)_{360nm}--.

Line 36, "OD 96 nm" should read --OD_{360 nm}--.

Column 24.

Line 11, "a-helix" should read -- α -helix--.

Column 25.

Line 8, "8. T. Irie" should read --8. Irie--.

Line 59, "140 (1987)" should read --1-40 (1987)--.

Line 64, "22. Wang et a." should read --22. Wang et al.--.